194 related articles for article (PubMed ID: 23886146)
1. Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Butthongkomvong K; Sirachainan E; Jhankumpha S; Kumdang S; Sukhontharot OU
Asian Pac J Cancer Prev; 2013; 14(6):3565-8. PubMed ID: 23886146
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
3. Clinical presentation and outcomes of patients with biliary malignancies: the Aga Khan University experience.
Kumar S; Masood N; Shaikh AJ; Valimuhammad AT; Haider G; Lal A; Niamatullah N
Asian Pac J Cancer Prev; 2009; 10(3):463-6. PubMed ID: 19640192
[TBL] [Abstract][Full Text] [Related]
4. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
Gusani NJ; Balaa FK; Steel JL; Geller DA; Marsh JW; Zajko AB; Carr BI; Gamblin TC
J Gastrointest Surg; 2008 Jan; 12(1):129-37. PubMed ID: 17851723
[TBL] [Abstract][Full Text] [Related]
5. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
Wirasorn K; Ngamprasertchai T; Khuntikeo N; Pakkhem A; Ungarereevittaya P; Chindaprasirt J; Sookprasert A
J Gastroenterol Hepatol; 2013 Dec; 28(12):1885-91. PubMed ID: 23829232
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Iqbal S; Rankin C; Lenz HJ; Gold PJ; Ahmad SA; El-Khoueiry AB; Messino MJ; Holcombe RF; Blanke CD
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1595-602. PubMed ID: 21556747
[TBL] [Abstract][Full Text] [Related]
8. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Chae H; Cho H; Yoo C; Kim KP; Jeong JH; Chang HM; Kang J; Lee HC; Lim YS; Kim KM; Shim JH; Lee SS; Park DH; Song TJ; Hwang S; Song GW; Moon DB; Lee YJ; Lee JH; Ryoo BY
Int J Biol Markers; 2018 Nov; 33(4):432-438. PubMed ID: 29874985
[TBL] [Abstract][Full Text] [Related]
10. [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Yu ZY; Ouyang XN; Chen ZS; Li J; Chen X; Xie FW
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):144-6. PubMed ID: 18646701
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Iyer RV; Gibbs J; Kuvshinoff B; Fakih M; Kepner J; Soehnlein N; Lawrence D; Javle MM
Ann Surg Oncol; 2007 Nov; 14(11):3202-9. PubMed ID: 17705089
[TBL] [Abstract][Full Text] [Related]
13. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
[No Abstract] [Full Text] [Related]
14. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
15. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Wiazzane N; Chauffert B; Ghiringhelli F
Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):614-8. PubMed ID: 23711827
[TBL] [Abstract][Full Text] [Related]
18. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
[TBL] [Abstract][Full Text] [Related]
19. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
Kim YI; Park JW; Kim BH; Woo SM; Kim TH; Koh YH; Lee WJ; Kim CM
Radiat Oncol; 2013 Dec; 8():292. PubMed ID: 24359879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]